Nootropics Index - Save on smarter supplements
Nootropics>Synthetic nootropics & research compounds>PPAP
Synthetic nootropics & research compounds

PPAP

Phenylpropylaminopentane (PPAP)

Phenylpropylaminopentane (PPAP) is a synthetic research compound represented in older animal and cell pharmacology literature. The reviewed source set does not establish human nootropic outcomes, pharmacokinetics, a consumer dose, or a safety margin. Historical rows name PPAP HCl bulk powder only, without a serving basis or active offer, so they do not support consumer dosing or price-per-dose claims.

Isolated CompoundSyntheticClinical ResearchMostly Animal EvidenceMostly In Vitro EvidenceInsufficient EvidenceForm Dependent Evidence
Updated August 2026/7 min read/11 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
Extra caution

Who should avoid this or get expert review first

This is not a recommendation to use. These groups should treat the profile as a reason to slow down and verify safety, rules, and personal context.

  • Audience avoidance9The profile uses a high baseline risk because the reviewed source set does not establish human dose, pharmacokinetics, adverse-event frequency, interactions, or long-term safety for this synthetic research compound. The concern is uncertainty at ordinary consumer exposure, not a claim of a measured human harm rate.
01

What is it?

Research-compound profile, not validated supplement evidence9
The reviewed PPAP literature is mainly animal and cell pharmacology with related BPAP context. It does not establish a human nootropic outcome, dose, pharmacokinetic profile, or safety margin.
Bulk powder quantity is not a consumer dose10
Historical PPAP HCl rows name 1 g and 2 g powder quantities, not serving instructions. Animal and cell-study conditions do not provide a consumer protocol.

What PPAP refers to

2

Phenylpropylaminopentane is commonly shortened to PPAP. PubChem has distinct freebase and hydrochloride records, while the historical NootropicsIndex rows specifically named PPAP HCl powder. Identity, salt form, and bulk quantity are separate facts from consumer dosing.

Human PPAP outcomes were not identified in the reviewed source set9
The reviewed literature and registry search did not provide direct human PPAP outcomes for focus, attention, wakefulness, mood, productivity, memory, or fatigue. This page leaves those as evidence gaps.
02

Names, aliases and forms

Common NamesPhenylpropylaminopentane; PPAP HCl
AcronymPPAP
Chemical Names1-Phenyl-2-propylaminopentane; N,alpha-dipropylbenzeneethanamine
Iupac Names(2R)-1-phenyl-N-propylpentan-2-amine; 1-phenyl-N-propylpentan-2-amine;hydrochloride
Cas Numbers784118-64-5; 119486-01-0
Pubchem Cids51529346; 23172541
Molecular FormulasC14H23N; C14H24ClN
InchikeysPBENSVGEGPJNFJ-CQSZACIVSA-N; QCJSIHKLYXENIM-UHFFFAOYSA-N
Regulatory NamesUNII-UZ3Q3C2Z57; UNII-JQS8BZ2WS9
03

Mechanisms of action

Catecholaminergic mechanism context is preclinical

4

A PPAP mechanism paper describes action-potential transmitter-release-coupling work in catecholaminergic systems. This is pharmacology context, not a human supplement outcome.

04

Potential effects and evidence map

Older animal and cell studies describe PPAP pharmacology and catecholaminergic activity-enhancer mechanisms. Related BPAP literature is distinct compound context, not direct PPAP evidence. The reviewed source set does not establish human cognitive outcomes, pharmacokinetics, dosing, or long-term supplement safety. Interpret this profile as preclinical research context, not evidence of focus, wakefulness, mood, productivity, or memory benefits in people.

Effect domainMagnitudeGrade
Mental energy / wakefulness3
UnknownConfidence: Low

Animal pharmacology does not establish a human wakefulness or energy effect.

Note No human dose, timing, or outcome can be inferred from the reviewed preclinical work.

0/5
D
Focus / attention4
UnknownConfidence: Low

No reviewed human PPAP attention outcome was identified.

Note Animal mechanism work is not a consumer focus claim.

0/5
D
Motivation / drive4
UnknownConfidence: Low

No reviewed human PPAP motivation or drive outcome was identified.

Note Mechanism terminology does not establish a user-facing outcome.

0/5
D
Memory / learning5
UnknownConfidence: Low

No reviewed human PPAP memory or learning outcome was identified.

Note Animal performance findings do not establish human memory enhancement.

0/5
D
05

Typical dosages and timing

Dose evidence10Not established

The compact dosage fields are blank. Historical PPAP HCl powder quantities and preclinical study conditions are not consumer dosing evidence.

06

Timing & effect horizon

Effect horizonUnknown
Unknown
Human PPAP timing data are not established9

The reviewed source set did not provide human onset, duration, The time for blood levels to fall by half during the final elimination phase.Source, repeat-dose safety, tolerance, or cycle fields for PPAP. The compact timing fields remain blank.

07

Safety, side effects and risk profile

Evidence uncertainty9
Confidence: High

The reviewed source set does not establish human dose, pharmacokinetics, efficacy, adverse-event frequency, or long-term safety.

Note This is the dominant limitation for a consumer-facing research-compound profile.

5/5
E
Overstimulation / insomnia3
Confidence: Low

Preclinical stimulant-like pharmacology creates an unresolved concern for stimulation and sleep disruption, but human frequency is not characterized.

Note This is a mechanism-based caution, not a quantified human adverse effect.

3/5
D
Cardiovascular caution4
Confidence: Low

Preclinical catecholaminergic pharmacology leaves cardiovascular effects unresolved because human heart-rate and blood-pressure studies were not identified.

Note The rating reflects uncertainty around a stimulant-like research compound rather than an observed human rate.

3/5
D
Interaction risk4
Confidence: Low

Human PPAP interaction studies were not identified, so the interaction profile cannot be characterized for consumer use.

Note Do not infer a safe combination profile from preclinical mechanism literature.

3/5
E
Dependence / withdrawal risk3
Confidence: Low

Tolerance, withdrawal, rebound, and misuse outcomes are not characterized for human PPAP use.

Note This is unresolved, not a claim of confirmed dependence.

3/5
E
Pregnancy / lactation caution9
Confidence: Medium

The reviewed source set does not establish PPAP safety during pregnancy, lactation, childhood, or neurodevelopment.

Note Absence of safety data is especially material for this synthetic research compound.

4/5
E
Legal / regulatory risk11
Confidence: Low

Current jurisdiction-specific PPAP status was not established by the reviewed source set.

Note The DEA source supplies general U.S. statutory background, not a PPAP-specific determination.

3/5
E
Headache / dizziness3
Confidence: Low

Headache and dizziness outcomes are not characterized in human PPAP studies because such studies were not identified.

Note Do not estimate symptoms from other stimulants or preclinical observations.

1/5
E
Core risk context3High uncertainty

PPAP has preclinical stimulant-like pharmacology but no reviewed human dose or adverse-event data. That combination makes the safety margin and practical risk profile unresolved.

Data gap9No safety margin established

The reviewed source set did not establish human adverse-event frequency, dose-response, organ safety, psychiatric outcomes, or withdrawal patterns for PPAP.

08

Interactions and cautions

Interaction evidence4

The reviewed source set did not provide human PPAP interaction studies. Preclinical mechanism terminology cannot establish a safe consumer combination profile.

09

Legal and regulatory status

United States, as of 2026-08-2111

The reviewed DEA material provides general U.S. controlled-substance background, not a PPAP-specific scheduling determination. Legal status, import rules, and product claims vary by country and require jurisdiction-specific review.

10

How it compares

Compound boundary6

BPAP occurs in related activity-enhancer literature but has a different structure and evidence record. It should not supply PPAP efficacy, dosing, or safety assumptions.

Translation boundary5

Animal studies can explain scientific interest in PPAP, but they do not provide a public human dose, safety margin, or reliable benefit expectation.

Related-compound boundary6

PPAP appears in literature alongside deprenyl/selegiline and BPAP, but these compounds have different structures and evidence records. This profile does not borrow dosing or safety assumptions across them.

11

Practical buying and quality notes

  • Historical Newmind rows name 1 g and 2 g PPAP HCl powder but do not provide a serving basis or active-offer information. They cannot support daily-cost or price-per-dose calculations.10
  • Historical product rows do not verify the current salt form, assay, batch identity, or testing record for any current offer. This page does not endorse a source or product quality claim.2
  • A bulk-powder quantity does not define a PPAP serving. Without validated human dosing evidence, the page does not calculate price per dose or daily cost.10
12

FAQ

Is PPAP a proven nootropic?

9

No. PPAP has animal and cell pharmacology context, but the reviewed source set did not establish a human nootropic outcome.

What is the PPAP dose?

10

No human PPAP dose was established in the reviewed source set. Historical 1 g and 2 g PPAP HCl powder rows are bulk quantities, not a serving protocol.

How long does PPAP last?

9

Human PPAP onset, duration, half-life, and cycle fields were not established in the reviewed source set, so the compact timing fields are blank.

Is PPAP HCl the same as PPAP?

2

PPAP HCl is a hydrochloride salt record distinct from the freebase record. Bulk quantities are not directly interchangeable without a stated identity and basis.

Is PPAP legal to buy?

11

The reviewed source set does not establish a jurisdiction-specific PPAP legal status. The cited U.S. material is general controlled-substance background, not a PPAP scheduling decision.

13

References

  1. PubChem. Phenylpropylaminopentane freebase (CID 51529346): identity and synonyms. Accessed 2026-08-21.
  2. PubChem. Phenylpropylaminopentane hydrochloride / PPAP HCl (CID 23172541): salt identity and synonyms. Accessed 2026-08-21.
  3. Knoll J, Knoll B, Torok Z. The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant. Arch Int Pharmacodyn Ther. 1992.
  4. Knoll J, Miklya I, Knoll B. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons. Life Sci. 1996.
  5. Knoll J, Knoll B, Miklya I. High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers. Life Sci. 1996.
  6. Knoll J, Yoneda F, Knoll B. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Br J Pharmacol. 1999.
  7. Miklya I, Knoll J. Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Life Sci. 2003.
  8. Csaba G, Kovacs P, Pallinger E. Acute and delayed effect of (-) deprenyl and (-) 1-phenyl-2-propylaminopentane (PPAP) on the serotonin content of peritoneal cells. Cell Biochem Funct. 2006.
  9. ClinicalTrials.gov search for the full chemical name phenylpropylaminopentane. Accessed 2026-08-21.
  10. NootropicsIndex legacy product-listing snapshot: Newmind PPAP HCl 1.0 g and 2.0 g powder rows, crawled 2020-06-06.
  11. U.S. Drug Enforcement Administration. Drug Scheduling and Controlled Substances Act overview. Accessed 2026-07-01.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.